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1099-i 15 N-T Pro-BNP Is a Powerful Predictor of Outcome in 
Patients With Stable Angina: A Substudy of the IONA 
Trial 
Stephen D. Robb, Theresa A. McDonagh. Michele Robertson, Ian Ford, Kim M. Fox, W. 
Stewart Hillis, John J. Morton, Henry J. Dargie, University of Glasgow, Glasgow, United 
Kingdom, Imperial College, London, United Kingdom 
Background: Levels of B-type natriuretic peptide (BNP) have been shown to predict out- 
come in heart failure, asymptomatic left ventricular systolic dysfunction and acute coro- 
nary syndromes. The prognostic value of BNP and the related peptide N-terminal 
proBNP have never been reported in stable angina. We report the relationship between 
NT-proBNP and outcome in partlclpants in the IONA study. 
Methods: The IONA (Impact of Nicorandil in Angina) study was a random&d, placebo 
controlled trial of nicorandil in stable angina, involving 5126 patients. It showed that the 
addltlon of nicorandil 20mg twice daily to standard antianginal therapy reduced major 
adverse coronary events. Plasma levels of NT-proBNP were measured at randomisation 
in a subset of 1427 of the participants in this trial. The demographics in this peptide sub- 
group were similar to the whole study group. A Cox model was used, splitting the group 
into two halves above and below the median value for NT-proBNP, to relate NT-proBNP 
levels to the main end points of the study. 
Results: Median levels of NT-proBNP were significantly higher in patients with each of 
the study endpoints: acute coronary syndrome - 531.5 v 188.0 pglml; coronary hearl dis- 
ease death or non fatal myocardial infarction (M.I.) 728.0 v 190.5 pg/ml, and all cause 
mortality - 706.5 v 191.0 pg/ml (all PcO.0001). Baseline levels of NT-proBNP were shown 
to be predictive of each of the endpoints: acute coronary syndromes HR 1.69 (1.31 - 
2.18); coronary heart disease death or non fatal M.I. - HR 3.86 (2.29 - 6.29) and all 
cause mortality - HR 3.26 (2.00 - 5.33). 
Conclusion: In patients with stable angina enrolled into the IONA trial circulating levels 
of NT-proBNP were a very powerful outcome indicator and could prove useful in assign- 
ing prognosis in patients with stable angina. 
1098-116 Serum Amyloid A Low-Density Lipoprotein Complex: A 
Novel Prognostic Marker in Stable Coronary Heart 
Disease 
Makoto Sahara, Ken Ogasawara, Tadanon Aizawa, Yoichirou Wada, Tatsuhiko Kodama, 
Shinichi Mashiba. Kazuo Uchida. The Cardiovascular Institute. Tokvo. Japan. Research . 
Center for Advanced Science and Technology, The Unwersity of Tokyo, Tokyo, Japan 
Purpose and methods: Although some reports have indicated that acute phase proteins 
such as C-reactive protein (CRP) and serum amyloid A (SAA) can predict the prognosis 
in patients with acute coronary syndrome, the value of these markers in stable coronary 
heart disease is still unclear. In this prospective cohort study, we evaluated SAA-LDL 
complex as a new marker for prediction of prognosis in addition to the ordinary markers 
including CRP, SAA and use of HMG-CoA reductase inhibitors or aspirin in consecutive 
140 patients with stable coronary heart disease who had at least 1 coronary artery steno- 
sis at the diagnostic coronary angiography (CAG). All the patients were followed up for 
18 months after CAG. Serum levels of SAA-LDL complex were measured by sandwich 
enzyme-linked immunosorbant assay. Results: End-point events occurred in 21 patients 
(2 deaths from myocardial infarction, 2 cerebral infarctions and 17 coronary revascular- 
ization procedures). Age, diabetes mellitus, triglyceride and SAA-LDL complex were 
selected as independent predictors by a multiple stepwise regression test. The result of a 
logistic regression test was as follows. 
Odds ratio Confidence interval 
Age (year) 1.14 1.05-l .25 
Diabetes mellitus 3.50 1.08-l 1.40 
Triglyceride (10mg/dl) 1.12 1.01-l .23 
SAA-LDL complex (lo~glml) 2.32 1.05-4.70 
Conclusions: Serum level of SAA-LDL complex can be a new marker for prediction of 
prognosis in patients with stable coronary heart disease. It is also suggested that SAA 
combmed with LDL may play an important role in the process of atherosclerosis. 
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822-1 Does the Extent of ST-Segment Depression Predict 
Short- and Long-Term Mortality in Patients With Non-ST 
Segment Elevation Acute Coronary Syndromes? 
Insights From the GUSTO IV 
Yulino Fu, Michael Lauer, Wei-Ching Chang, Robert M. Califf, Maarten L. Simoons. Lars 
Wallentin, Eric J. Topol, Paul W. Armstrong, for the GUSTO IV Investigators, University 
of Albelta, Edmonton, AB, Canada 
ST depression (ST dep) bO.5 mm is widely used for risk stratification. However, the 
extent of ST dep as a predictor of short and long term mortality in NSTEMI acute coro- 
navy syndromes (ACS) is not well studied. Methods: 7741 of 7780 patients (pts) with 
ACS in GUSTO IV had baseline ECGs read in a core lab blinded to outcomes. ST dep 
was assessed in 0.5 mm increments. Results: 300 pts (3.9%) died at 30 davs and 644 
(8.3%) by 1 year. Pts with ECG confounders (514j had 30-&y and 1-year’mottality of 
6.9% and 18.3%. respectivelv. There was an increased risk of death with each 0.5 mm 
increment in ST dep ifigure): After adjusting for baseline characteristics, troponin (TnT), 
and C reactive protein (CRP), the extent of ST dep was the most powerful predlctor of 
30-day death and the second most powerful at 1 year after age. ST quantitative analysis 
vs conventional cut point of >= 0.5 mm Improved the ECG predictive power for 30.day 
and l-year mortality to 20.8% and 10.2% vs 7.3% and 4.0%, respectively. The relative 
contribution of baseline biomarkers to mortality were: (a) 4.4% for TnT at 30days, which 
was 22.7% of the predictive power of ST dep; and (b) 3.6% and 2.1%, respectively, for 
TnT and CRP at 1 year, which were 36.7% and 21.7% of the predictive power of quanti- 
tative ST dep. Conclusion: Quantitative ST analysx provides major incremental prognos- 
tic Insight over dichotomous assessment of >=0.5mm. Despite enthusiasm for new 
biomarkers, it is superior to TnT at 30 days and a more significant moltality predictor than 
either TnT or CRP at 1 -year. 
2:15 p.m. 
822-2 A High-Grade Stenosis After Successful Fibrinolysis 
Does Not Predict Death and Reinfarction: lo-Year 
Follow-Up of the APRICOT-l Trial 
Marc A. Brouwer, Peter C. Kievit, Gerrit Veen, Freek W. A. Verheugt, Free University 
Medical Center, Amsterdam, The Netherlands, Heartcenter, University Medical Center, 
Nijmegen, The Netherlands 
Background: In lack of randomized trials in the current era, the potential benefit of a rou- 
tine invasive strategy on outcome following successful fibrinolytic therapy is uncertain. 
This study addresses the impact of a high-grade stenosis on both short-and long-term 
clinical outcome in the setting of a conservative revascularization strategy. 
Methods: In the APRICOT-1 trial (1987-1991) 248 patients had fibrinolysls for suspected 
acute myocardial infarction with a patent Infarct artery at 24.hour anglography, and fol- 
low-up angiography at 3 months. QCA-analysis was possible in 240 patients, a > 60% 
considered significant. Revascularization rate at 3 months was 11%. 
Results: Death and/or reinfarction rates at 3 months were 8% for those with a significant 
stenosis and 10% for those with a < 60% stenosis at baseline (p=ns). Long-term infarct- 
free survival did not differ either (figure). 
Conclusion: These observations challenge the hypothesis that patlents with a high- 
